Janney Montgomery Scott
NMTR

Janney Montgomery Scott’s 9 Meters Biopharma NMTR Stock Holding History

Janney Montgomery Scott’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,000
Closed -$33K – 2289
2020
Q3 		$33K Buy
2,000
+850
+74% +$10.3K ﹤0.01% 2048
2020
Q2 		$13K Buy
+1,150
New +$13K ﹤0.01% 1982

Other funds holding NMTR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Janney Montgomery Scott's NMTR Position: Q4 2020 in Review

Janney Montgomery Scott sold out of 9 Meters Biopharma (NMTR) in Q4 2020, closing a stake of 2,000 shares — an estimated $33K sold.

Janney Montgomery Scott first reported a position in NMTR in Q2 2020 and held it in 2 quarters. The position peaked at $33K in Q3 2020. 57 funds tracked by Wall St. Rank hold NMTR as of Q4 2020.

  • Janney Montgomery Scott reported no remaining 9 Meters Biopharma position as of Q4 2020 after selling out during the quarter.
  • Janney Montgomery Scott sold 2,000 9 Meters Biopharma shares in Q4 2020, an estimated $33K.
  • Janney Montgomery Scott first reported a position in 9 Meters Biopharma in Q2 2020 and held it in 2 quarters.
  • Janney Montgomery Scott's 9 Meters Biopharma position peaked at $33K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2020.

Based on Janney Montgomery Scott's 13F filing for Q4 2020, filed 25 Jan 2021.